Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
8.81
+0.76 (9.43%)
Nov 21, 2024, 12:30 PM EST - Market open
Altimmune Employees
Altimmune had 59 employees as of December 31, 2023. The number of employees increased by 7 or 13.46% compared to the previous year.
Employees
59
Change (1Y)
7
Growth (1Y)
13.46%
Revenue / Employee
$881
Profits / Employee
-$1,754,576
Market Cap
619.50M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Auna S.A. | 14,958 |
Talkspace | 472 |
Pharming Group | 382 |
SI-BONE | 344 |
PureTech Health | 90 |
Olema Pharmaceuticals | 74 |
Astria Therapeutics | 59 |
Savara | 37 |
ALT News
- 6 days ago - Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - GlobeNewsWire
- 7 days ago - Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge - Seeking Alpha
- 7 days ago - Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health - Seeking Alpha
- 9 days ago - Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - GlobeNewsWire
- 14 days ago - Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - GlobeNewsWire
- 15 days ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire